Skip to main content
Figure 21 | BMC Complementary and Alternative Medicine

Figure 21

From: Umbelliferone β-D-galactopyranoside from Aegle marmelos (L.) corr. an ethnomedicinal plant with antidiabetic, antihyperlipidemic and antioxidative activity

Figure 21

Effect of umbelliferone β-D-galactopyranoside (UFG) on histopathology study of kidney in different groups of rat: (A) Normal control: Normal control group rat histopathology shown normal size of glomerulus (B) Diabetic control: Diabetic control rat histopathology shown inflammatory cell in blood vessels (blue arrow) and deposition of fats (yellow arrow) (C) UFG I (10 mg/kg): Tested drug UFG (10 mg/kg) treated group rat histopathology shown inflammation in blood vessels (brown arrow) and fat deposition (yellow arrow) (D) UFG II (20 mg/kg): Dose UFG (20 mg/kg) treated group rat histopathology shown only fat deposition (yellow arrow) no inflammatory blood cells. (E) UFG III (40 mg/kg): Treatment with dose UFG (40 mg/kg) group rat histopathology shown kidney histopathology like the glibenclamide treated group (F) Glibenclamide (10 mg/kg): Histopathology of Glibenclamide treated group rat shown the normal kidney. The samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .

Back to article page